Rec'd PCT/PTO 13 MAR 2006

PCT

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. RLL-262US

In Re Application Of: GOGIA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/518,972		Unknown	26815	Unknown	2913

Title: PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. RLL-262US

In Re Application of: GOGIA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/518,972		Unknown	26815	Unknown	2913

Title: PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

☐ A check in the amount of is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.

- ☐ Charge the amount of
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on March 17, 2006 (CE)

(Date)

Signature of Person Mailing Correspondence

Christine Kenedy

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

William Hare

Signature

Dated: March , 2006

William D. Hare, Esq.
Reg. No. 44,739

CUSTOMER NO. 26,815

cc:

P10A/REV05

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-262US	Serial No.: 10/518,972
	Applicants: GOGIA *et al.*	
SUPPLEMENTAL	Filed:	Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES / NO

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

/M.M./	S1C1	"Chapter 5: Granulation and Tablet Characteristics" in Leiberman and Lachman, eds. *Pharmaceutical Dosage Forms - Tablets, Volume 2.* New York: Marcel Dekker, Inc., 185-205 and 261-267 (1981)
/M.M./	S1C2	Summers and Aulton, 2001. "Chapter 25: Granulation" in Aulton, ed. *Pharmaceutics: The Science of Dosage Form Design.* 2nd Edition. USA: Churchill Livingstone, 364-378.
/M.M./	S1C3	Kassem et al, "Effect of granule size on physical standards of tablets", *Manufacturing Chemist and Aerosol News,* 24-27 (1972)
/M.M./	S1C4	Yajima et al, "Optimization of Size Distribution of Granules for Tablet Compression[1)]", *Chemical and Pharmaceutical Bulletin,* 44(5):1056-1060 (1996)
/M.M./	S1C5	Řehula, 1985. "The Effect of Granule Size on Dissolution of Drugs from Tablets" in *Universitas Carolina Pragensis, Folia Pharmaceutica VIII.* Czechoslovakia:Univerzita Karlova (Charles University), 101-107.
/M.M./	S1C6	Miyamoto et al, "Optimization of the Granulation Process for Designing Tablets", *Chemical and Pharmaceutical Bulletin,* 46(9):1432-1437 (1998)
/M.M./	S1C7	Sheth et al, 1980. "Chapter 3: Compressed Tablets" in Leiberman and Lachman, eds. *Pharmaceutical Dosage Forms - Tablets, Volume 1.* New York: Marcel Dekker, Inc., 109-185.
/M.M./	S1C8	Planinšek et al, "The utilization of surface free-energy parameters for the selection of a suitable binder in fluidized bed granulation", *International Journal of Pharmaceutics,* 207:77-88 (2000)

EXAMINER	/Manu Manohar/	**DATE CONSIDERED**	08/13/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 **PAGE 1 OF 1**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./